The SRV LHPL centre of excellence in robotic orthopaedics will be helmed by joint replacement surgeon, Dr Narendra Vaidya
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
John Shaw, who is a Glasgow University graduate, along with his wife Kiran Mazumdar-Shaw had gifted US $ 7.5 million to the university in July 2019
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Subscribe To Our Newsletter & Stay Updated
